Literature DB >> 19776746

20 years studying p53 functions in genetically engineered mice.

Lawrence A Donehower1, Guillermina Lozano.   

Abstract

Cell and molecular biological studies of p53 functions over the past 30 years have been complemented in the past 20 years by studies that use genetically engineered mice. As expected, mice that have mutant Trp53 alleles usually develop cancers of various types more rapidly than their counterparts that have wild-type Trp53 genes. These mouse studies have been instrumental in providing important new insights into p53 tumour suppressor function. Such studies have been facilitated by the development of increasingly sophisticated genetic engineering approaches, which allow the more precise manipulation of p53 structure and function in a mammalian model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776746     DOI: 10.1038/nrc2731

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  135 in total

1.  Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.

Authors:  C Kuperwasser; G D Hurlbut; F S Kittrell; E S Dickinson; R Laucirica; D Medina; S P Naber; D J Jerry
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

2.  Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool.

Authors:  J L Luo; Q Yang; W M Tong; M Hergenhahn; Z Q Wang; M Hollstein
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

3.  p53 mutant mice that display early ageing-associated phenotypes.

Authors:  Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

4.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

5.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

6.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

7.  Telomerase reverse transcriptase delays aging in cancer-resistant mice.

Authors:  Antonia Tomás-Loba; Ignacio Flores; Pablo J Fernández-Marcos; María L Cayuela; Antonio Maraver; Agueda Tejera; Consuelo Borrás; Ander Matheu; Peter Klatt; Juana M Flores; José Viña; Manuel Serrano; Maria A Blasco
Journal:  Cell       Date:  2008-11-14       Impact factor: 41.582

8.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

9.  TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.

Authors:  Richard Tomasini; Katsuya Tsuchihara; Margareta Wilhelm; Masashi Fujitani; Alessandro Rufini; Carol C Cheung; Fatima Khan; Annick Itie-Youten; Andrew Wakeham; Ming-Sound Tsao; Juan L Iovanna; Jeremy Squire; Igor Jurisica; David Kaplan; Gerry Melino; Andrea Jurisicova; Tak W Mak
Journal:  Genes Dev       Date:  2008-09-19       Impact factor: 11.361

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  106 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  p53 and microRNA-34 are suppressors of canonical Wnt signaling.

Authors:  Nam Hee Kim; Hyun Sil Kim; Nam-Gyun Kim; Inhan Lee; Hyung-Seok Choi; Xiao-Yan Li; Shi Eun Kang; So Young Cha; Joo Kyung Ryu; Jung Min Na; Changbum Park; Kunhong Kim; Sanghyuk Lee; Barry M Gumbiner; Jong In Yook; Stephen J Weiss
Journal:  Sci Signal       Date:  2011-11-01       Impact factor: 8.192

3.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

Review 4.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 5.  p53 at a glance.

Authors:  Colleen A Brady; Laura D Attardi
Journal:  J Cell Sci       Date:  2010-08-01       Impact factor: 5.285

6.  The ups and downs of p53 regulation in hematopoietic stem cells.

Authors:  Hussein A Abbas; Vinod Pant; Guillermina Lozano
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

Review 7.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 8.  Linking functional decline of telomeres, mitochondria and stem cells during ageing.

Authors:  Ergün Sahin; Ronald A Depinho
Journal:  Nature       Date:  2010-03-25       Impact factor: 49.962

9.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

10.  miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.

Authors:  G Yang; Y Gong; Q Wang; L Wang; X Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.